 Liron Caplan
Concepts (337)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spondylitis, Ankylosing | 11 | 2024 | 42 | 5.680 |
Why?
| | Arthritis, Rheumatoid | 51 | 2019 | 989 | 5.680 |
Why?
| | Rheumatology | 15 | 2023 | 87 | 4.900 |
Why?
| | Antirheumatic Agents | 27 | 2019 | 254 | 4.080 |
Why?
| | Spondylarthritis | 9 | 2024 | 35 | 3.770 |
Why?
| | Osteoporosis | 10 | 2023 | 229 | 2.160 |
Why?
| | Glucocorticoids | 10 | 2023 | 545 | 1.760 |
Why?
| | Severity of Illness Index | 26 | 2023 | 2674 | 1.740 |
Why?
| | Health Literacy | 5 | 2019 | 169 | 1.690 |
Why?
| | Gastrointestinal Diseases | 3 | 2018 | 187 | 1.650 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 4 | 2023 | 304 | 1.500 |
Why?
| | Methotrexate | 11 | 2018 | 227 | 1.280 |
Why?
| | Arthritis | 2 | 2019 | 112 | 1.210 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 3 | 2015 | 245 | 1.160 |
Why?
| | Registries | 20 | 2018 | 1810 | 1.130 |
Why?
| | Decision Support Systems, Management | 2 | 2015 | 6 | 1.030 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2014 | 35 | 0.930 |
Why?
| | Sacroiliitis | 1 | 2022 | 3 | 0.900 |
Why?
| | Cardiovascular Diseases | 9 | 2023 | 1798 | 0.840 |
Why?
| | Fractures, Bone | 3 | 2023 | 380 | 0.820 |
Why?
| | Bone Density Conservation Agents | 4 | 2014 | 61 | 0.820 |
Why?
| | Health Knowledge, Attitudes, Practice | 4 | 2015 | 1185 | 0.760 |
Why?
| | Veterans | 13 | 2019 | 1208 | 0.760 |
Why?
| | Humans | 97 | 2024 | 118974 | 0.760 |
Why?
| | Body Mass Index | 10 | 2018 | 2092 | 0.760 |
Why?
| | Arthritis, Psoriatic | 2 | 2023 | 16 | 0.750 |
Why?
| | Outpatient Clinics, Hospital | 2 | 2011 | 79 | 0.750 |
Why?
| | Transportation | 1 | 2019 | 42 | 0.710 |
Why?
| | Rheumatic Diseases | 2 | 2018 | 49 | 0.700 |
Why?
| | Drug Packaging | 1 | 2019 | 44 | 0.690 |
Why?
| | Inflammatory Bowel Diseases | 3 | 2018 | 290 | 0.680 |
Why?
| | Gastrointestinal Tract | 2 | 2018 | 175 | 0.670 |
Why?
| | Aged | 44 | 2019 | 19657 | 0.670 |
Why?
| | Conflict of Interest | 1 | 2020 | 120 | 0.660 |
Why?
| | United States | 33 | 2023 | 12555 | 0.650 |
Why?
| | Visual Analog Scale | 2 | 2019 | 31 | 0.650 |
Why?
| | Middle Aged | 48 | 2019 | 27617 | 0.640 |
Why?
| | Antibodies, Antineutrophil Cytoplasmic | 1 | 2018 | 35 | 0.630 |
Why?
| | Joints | 3 | 2013 | 85 | 0.630 |
Why?
| | Pharmaceutical Preparations | 1 | 2019 | 167 | 0.610 |
Why?
| | Vasculitis | 1 | 2018 | 75 | 0.610 |
Why?
| | Disability Evaluation | 2 | 2018 | 280 | 0.600 |
Why?
| | Diphosphonates | 3 | 2014 | 50 | 0.590 |
Why?
| | Medication Therapy Management | 1 | 2018 | 72 | 0.590 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2018 | 136 | 0.570 |
Why?
| | Cross-Sectional Studies | 16 | 2019 | 4552 | 0.560 |
Why?
| | Male | 57 | 2022 | 57801 | 0.560 |
Why?
| | Health Care Costs | 1 | 2019 | 394 | 0.520 |
Why?
| | Patient Satisfaction | 2 | 2019 | 610 | 0.520 |
Why?
| | Surveys and Questionnaires | 7 | 2016 | 4708 | 0.520 |
Why?
| | Weight Loss | 5 | 2018 | 655 | 0.520 |
Why?
| | Liver Diseases | 1 | 2018 | 282 | 0.520 |
Why?
| | Attitude of Health Personnel | 2 | 2013 | 992 | 0.510 |
Why?
| | Patient Education as Topic | 4 | 2015 | 699 | 0.510 |
Why?
| | Practice Patterns, Physicians' | 3 | 2015 | 1200 | 0.510 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2022 | 2174 | 0.510 |
Why?
| | gamma-Glutamyl Hydrolase | 1 | 2014 | 2 | 0.490 |
Why?
| | Peptide Synthases | 1 | 2014 | 3 | 0.490 |
Why?
| | Veterans Health | 5 | 2017 | 167 | 0.480 |
Why?
| | Patient Reported Outcome Measures | 1 | 2016 | 252 | 0.480 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2015 | 111 | 0.480 |
Why?
| | Female | 50 | 2019 | 61565 | 0.480 |
Why?
| | Risk Factors | 24 | 2023 | 9000 | 0.470 |
Why?
| | Lipids | 2 | 2014 | 607 | 0.470 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 811 | 0.460 |
Why?
| | Proteins | 1 | 2019 | 938 | 0.460 |
Why?
| | Spondylarthropathies | 3 | 2019 | 6 | 0.460 |
Why?
| | Health Status | 3 | 2018 | 726 | 0.460 |
Why?
| | Societies, Medical | 5 | 2019 | 703 | 0.460 |
Why?
| | Biomedical Research | 1 | 2019 | 612 | 0.460 |
Why?
| | Activities of Daily Living | 1 | 2016 | 354 | 0.450 |
Why?
| | Folic Acid | 1 | 2014 | 161 | 0.440 |
Why?
| | Symptom Assessment | 1 | 2013 | 123 | 0.440 |
Why?
| | Consumer Behavior | 1 | 2013 | 64 | 0.430 |
Why?
| | Pharmacists | 1 | 2015 | 238 | 0.430 |
Why?
| | Physical Therapy Modalities | 1 | 2015 | 274 | 0.430 |
Why?
| | Electronic Health Records | 3 | 2015 | 829 | 0.430 |
Why?
| | Health Personnel | 3 | 2014 | 588 | 0.430 |
Why?
| | Obesity | 5 | 2018 | 2746 | 0.410 |
Why?
| | Tumor Necrosis Factor-alpha | 7 | 2018 | 1171 | 0.410 |
Why?
| | Hospitals, Public | 1 | 2011 | 24 | 0.410 |
Why?
| | Prednisone | 5 | 2018 | 235 | 0.390 |
Why?
| | Telemedicine | 1 | 2019 | 664 | 0.370 |
Why?
| | Anti-Inflammatory Agents | 4 | 2018 | 465 | 0.360 |
Why?
| | Autoantibodies | 5 | 2019 | 1335 | 0.360 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 126 | 0.350 |
Why?
| | Cerebrovascular Disorders | 3 | 1997 | 86 | 0.350 |
Why?
| | Workflow | 1 | 2010 | 148 | 0.340 |
Why?
| | Adalimumab | 4 | 2020 | 43 | 0.340 |
Why?
| | Physician-Patient Relations | 2 | 2011 | 490 | 0.340 |
Why?
| | Musculoskeletal Diseases | 1 | 2010 | 68 | 0.340 |
Why?
| | Linear Models | 5 | 2019 | 827 | 0.330 |
Why?
| | Practice Guidelines as Topic | 5 | 2018 | 1440 | 0.320 |
Why?
| | Publications | 1 | 2008 | 42 | 0.320 |
Why?
| | United States Department of Veterans Affairs | 8 | 2016 | 555 | 0.320 |
Why?
| | Ethics, Medical | 1 | 2008 | 73 | 0.310 |
Why?
| | Patient Compliance | 1 | 2012 | 537 | 0.310 |
Why?
| | Adult | 20 | 2023 | 31512 | 0.300 |
Why?
| | Aged, 80 and over | 11 | 2019 | 6561 | 0.300 |
Why?
| | Etanercept | 3 | 2016 | 51 | 0.300 |
Why?
| | Diabetes Mellitus | 1 | 2015 | 942 | 0.290 |
Why?
| | Infliximab | 3 | 2016 | 94 | 0.290 |
Why?
| | Ambulatory Care | 1 | 2010 | 482 | 0.280 |
Why?
| | Radiography | 3 | 2019 | 861 | 0.280 |
Why?
| | Treatment Outcome | 13 | 2019 | 9342 | 0.280 |
Why?
| | Time Factors | 11 | 2018 | 6412 | 0.270 |
Why?
| | Drug Utilization | 3 | 2018 | 169 | 0.270 |
Why?
| | Professional Practice | 1 | 2005 | 62 | 0.260 |
Why?
| | Quality of Life | 1 | 2016 | 2366 | 0.260 |
Why?
| | Longitudinal Studies | 9 | 2019 | 2513 | 0.260 |
Why?
| | Peptides, Cyclic | 4 | 2016 | 260 | 0.250 |
Why?
| | Pain | 1 | 2010 | 735 | 0.240 |
Why?
| | Reproducibility of Results | 5 | 2016 | 2874 | 0.240 |
Why?
| | Cohort Studies | 11 | 2015 | 5116 | 0.240 |
Why?
| | Predictive Value of Tests | 5 | 2018 | 1868 | 0.230 |
Why?
| | Rheumatoid Factor | 3 | 2016 | 156 | 0.230 |
Why?
| | Retrospective Studies | 11 | 2022 | 12978 | 0.230 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2019 | 2062 | 0.230 |
Why?
| | Adrenal Cortex Hormones | 1 | 2007 | 521 | 0.230 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2014 | 1945 | 0.230 |
Why?
| | Bone Density | 4 | 2023 | 449 | 0.230 |
Why?
| | Evidence-Based Medicine | 2 | 2018 | 693 | 0.220 |
Why?
| | Myocardial Infarction | 3 | 2018 | 968 | 0.220 |
Why?
| | Inflammation | 4 | 2018 | 2566 | 0.210 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2022 | 1244 | 0.210 |
Why?
| | Biomarkers | 5 | 2022 | 3588 | 0.210 |
Why?
| | Prognosis | 6 | 2016 | 3443 | 0.200 |
Why?
| | Lymphocytes | 1 | 2022 | 347 | 0.190 |
Why?
| | C-Reactive Protein | 3 | 2017 | 360 | 0.190 |
Why?
| | Proportional Hazards Models | 6 | 2016 | 1125 | 0.190 |
Why?
| | Multivariate Analysis | 8 | 2018 | 1474 | 0.190 |
Why?
| | Neutrophils | 2 | 2024 | 1233 | 0.190 |
Why?
| | Risk Assessment | 7 | 2018 | 3057 | 0.190 |
Why?
| | Granuloma, Foreign-Body | 1 | 2020 | 10 | 0.180 |
Why?
| | Tattooing | 1 | 2020 | 10 | 0.180 |
Why?
| | Regression Analysis | 3 | 2011 | 983 | 0.180 |
Why?
| | Comorbidity | 6 | 2018 | 1527 | 0.180 |
Why?
| | Malondialdehyde | 1 | 2019 | 30 | 0.180 |
Why?
| | Acetaldehyde | 1 | 2019 | 20 | 0.180 |
Why?
| | Blood Platelets | 1 | 2022 | 369 | 0.180 |
Why?
| | HLA-B27 Antigen | 1 | 2019 | 11 | 0.180 |
Why?
| | Macular Edema | 1 | 2020 | 36 | 0.180 |
Why?
| | Genotype | 3 | 2014 | 1882 | 0.170 |
Why?
| | Drug Stability | 1 | 2019 | 153 | 0.170 |
Why?
| | Drug Compounding | 1 | 2019 | 90 | 0.170 |
Why?
| | Deprescriptions | 1 | 2019 | 27 | 0.170 |
Why?
| | Blood Glucose | 4 | 2022 | 1939 | 0.170 |
Why?
| | Protein Stability | 1 | 2019 | 164 | 0.170 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2019 | 25 | 0.170 |
Why?
| | Uveitis | 1 | 2020 | 116 | 0.170 |
Why?
| | Intraepithelial Lymphocytes | 1 | 2018 | 12 | 0.160 |
Why?
| | Metformin | 1 | 2022 | 295 | 0.160 |
Why?
| | Clinical Trials as Topic | 2 | 2022 | 969 | 0.160 |
Why?
| | Hydroxychloroquine | 2 | 2018 | 59 | 0.160 |
Why?
| | Pyrroles | 1 | 2019 | 191 | 0.160 |
Why?
| | Vertebrobasilar Insufficiency | 1 | 1998 | 7 | 0.160 |
Why?
| | Mesencephalon | 1 | 1998 | 57 | 0.160 |
Why?
| | Cerebral Infarction | 1 | 1998 | 45 | 0.160 |
Why?
| | Piperidines | 1 | 2019 | 171 | 0.160 |
Why?
| | Stress, Mechanical | 1 | 2019 | 443 | 0.160 |
Why?
| | Obesity, Abdominal | 1 | 2017 | 39 | 0.150 |
Why?
| | Medication Adherence | 2 | 2012 | 556 | 0.150 |
Why?
| | Remission Induction | 3 | 2012 | 247 | 0.150 |
Why?
| | Inflammation Mediators | 2 | 2017 | 502 | 0.150 |
Why?
| | Absorptiometry, Photon | 3 | 2017 | 229 | 0.150 |
Why?
| | Thrombolytic Therapy | 1 | 1997 | 118 | 0.150 |
Why?
| | Temperature | 1 | 2019 | 622 | 0.150 |
Why?
| | Biological Products | 1 | 2019 | 170 | 0.140 |
Why?
| | Drug Administration Schedule | 2 | 2010 | 736 | 0.140 |
Why?
| | Pyrimidines | 1 | 2019 | 382 | 0.140 |
Why?
| | Genetic Predisposition to Disease | 3 | 2019 | 2275 | 0.140 |
Why?
| | Research Design | 1 | 2022 | 969 | 0.140 |
Why?
| | Sodium Chloride | 1 | 2016 | 144 | 0.140 |
Why?
| | Tissue Plasminogen Activator | 1 | 1997 | 231 | 0.130 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2019 | 667 | 0.130 |
Why?
| | DNA Methylation | 1 | 2019 | 503 | 0.130 |
Why?
| | Patient Selection | 3 | 2022 | 676 | 0.130 |
Why?
| | Genes, rel | 1 | 2014 | 4 | 0.130 |
Why?
| | Lung Diseases, Interstitial | 1 | 2019 | 464 | 0.120 |
Why?
| | Lipoproteins, HDL | 1 | 2014 | 82 | 0.120 |
Why?
| | Magnetic Resonance Imaging | 3 | 2022 | 3174 | 0.120 |
Why?
| | Hand | 1 | 2015 | 137 | 0.120 |
Why?
| | Lipoproteins, LDL | 1 | 2014 | 138 | 0.120 |
Why?
| | Disease Management | 1 | 2018 | 571 | 0.120 |
Why?
| | Incidence | 7 | 2018 | 2424 | 0.120 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1384 | 0.120 |
Why?
| | Femoral Fractures | 1 | 2014 | 67 | 0.110 |
Why?
| | Immunosuppressive Agents | 3 | 2009 | 681 | 0.110 |
Why?
| | Vascular Calcification | 1 | 2015 | 123 | 0.110 |
Why?
| | Nanoparticles | 1 | 2016 | 325 | 0.110 |
Why?
| | Spinal Fractures | 1 | 2014 | 77 | 0.110 |
Why?
| | Adiposity | 1 | 2017 | 516 | 0.110 |
Why?
| | North America | 1 | 2013 | 266 | 0.110 |
Why?
| | Immunoglobulin G | 1 | 2016 | 788 | 0.110 |
Why?
| | Dyslipidemias | 1 | 2014 | 162 | 0.110 |
Why?
| | Chronic Disease | 2 | 2018 | 1636 | 0.110 |
Why?
| | Health Services Research | 1 | 2015 | 385 | 0.100 |
Why?
| | Insurance, Pharmaceutical Services | 1 | 2011 | 21 | 0.100 |
Why?
| | Autoimmunity | 1 | 2018 | 831 | 0.100 |
Why?
| | Triglycerides | 1 | 2014 | 519 | 0.100 |
Why?
| | Lung Diseases | 1 | 2018 | 718 | 0.100 |
Why?
| | Antibodies, Monoclonal | 2 | 2016 | 1284 | 0.100 |
Why?
| | Coronary Artery Disease | 1 | 2018 | 647 | 0.100 |
Why?
| | Gastrointestinal Microbiome | 1 | 2018 | 548 | 0.100 |
Why?
| | Polymorphism, Genetic | 2 | 2011 | 642 | 0.100 |
Why?
| | Young Adult | 3 | 2019 | 10793 | 0.100 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2011 | 88 | 0.100 |
Why?
| | Workload | 1 | 2012 | 128 | 0.100 |
Why?
| | Memory Disorders | 1 | 2012 | 168 | 0.100 |
Why?
| | Glutathione Transferase | 1 | 2010 | 97 | 0.090 |
Why?
| | Sex Factors | 4 | 2017 | 1781 | 0.090 |
Why?
| | Carcinoma, Basal Cell | 1 | 2011 | 67 | 0.090 |
Why?
| | Follow-Up Studies | 4 | 2015 | 4596 | 0.090 |
Why?
| | Health Care Surveys | 1 | 2012 | 546 | 0.090 |
Why?
| | HLA-DR Antigens | 1 | 2010 | 224 | 0.090 |
Why?
| | Hospitalization | 2 | 2011 | 1785 | 0.090 |
Why?
| | Pilot Projects | 1 | 2014 | 1419 | 0.090 |
Why?
| | Health Surveys | 2 | 2012 | 454 | 0.090 |
Why?
| | Interviews as Topic | 1 | 2012 | 599 | 0.090 |
Why?
| | Disease Progression | 4 | 2019 | 2490 | 0.090 |
Why?
| | Hypertension | 1 | 2018 | 1203 | 0.090 |
Why?
| | Hip Fractures | 1 | 2010 | 79 | 0.080 |
Why?
| | Prospective Studies | 4 | 2013 | 6471 | 0.080 |
Why?
| | Self Care | 1 | 2011 | 357 | 0.080 |
Why?
| | Vitamin D Deficiency | 1 | 2010 | 162 | 0.080 |
Why?
| | Epitopes | 1 | 2010 | 443 | 0.080 |
Why?
| | Cytokines | 1 | 2016 | 1900 | 0.080 |
Why?
| | Immunocompromised Host | 2 | 2011 | 200 | 0.080 |
Why?
| | Databases, Bibliographic | 1 | 2008 | 29 | 0.080 |
Why?
| | Beneficence | 1 | 2008 | 18 | 0.080 |
Why?
| | Neoplasms | 3 | 2017 | 2179 | 0.080 |
Why?
| | Awards and Prizes | 1 | 1989 | 57 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 1795 | 0.080 |
Why?
| | Drug Prescriptions | 1 | 2010 | 248 | 0.080 |
Why?
| | Social Justice | 1 | 2008 | 63 | 0.080 |
Why?
| | Administration, Oral | 1 | 2010 | 756 | 0.080 |
Why?
| | Urban Population | 1 | 2010 | 409 | 0.080 |
Why?
| | Algorithms | 1 | 1994 | 1541 | 0.070 |
Why?
| | Research Personnel | 1 | 1989 | 158 | 0.070 |
Why?
| | Qualitative Research | 1 | 2012 | 953 | 0.070 |
Why?
| | Self Administration | 1 | 2007 | 125 | 0.070 |
Why?
| | Infusions, Intravenous | 2 | 2016 | 380 | 0.070 |
Why?
| | Depressive Disorder | 1 | 2009 | 333 | 0.070 |
Why?
| | Quality of Health Care | 1 | 2011 | 586 | 0.070 |
Why?
| | Military Personnel | 1 | 2013 | 529 | 0.070 |
Why?
| | Age Factors | 4 | 2015 | 2995 | 0.070 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2011 | 610 | 0.070 |
Why?
| | Respiratory Tract Diseases | 2 | 2017 | 143 | 0.070 |
Why?
| | Herpes Zoster | 1 | 2009 | 336 | 0.060 |
Why?
| | Cause of Death | 2 | 2017 | 380 | 0.060 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2013 | 765 | 0.060 |
Why?
| | Disabled Persons | 1 | 2007 | 147 | 0.060 |
Why?
| | CARD Signaling Adaptor Proteins | 1 | 2024 | 17 | 0.060 |
Why?
| | Databases, Factual | 3 | 2014 | 1231 | 0.060 |
Why?
| | Th17 Cells | 1 | 2024 | 57 | 0.060 |
Why?
| | Skin Neoplasms | 1 | 2011 | 762 | 0.060 |
Why?
| | Coculture Techniques | 1 | 2024 | 208 | 0.060 |
Why?
| | Interleukin-17 | 1 | 2024 | 105 | 0.060 |
Why?
| | Survival Analysis | 2 | 2018 | 1267 | 0.060 |
Why?
| | Adolescent | 3 | 2019 | 18480 | 0.060 |
Why?
| | Autoantigens | 2 | 2019 | 397 | 0.060 |
Why?
| | Isoxazoles | 2 | 2016 | 56 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2019 | 3171 | 0.050 |
Why?
| | Prevalence | 1 | 2007 | 2326 | 0.050 |
Why?
| | Pneumonia | 1 | 2006 | 592 | 0.050 |
Why?
| | Foreign-Body Reaction | 1 | 2020 | 23 | 0.050 |
Why?
| | Phospholipase D | 1 | 2019 | 7 | 0.040 |
Why?
| | Steroids | 1 | 2020 | 153 | 0.040 |
Why?
| | Machine Learning | 1 | 2022 | 331 | 0.040 |
Why?
| | Sulfasalazine | 1 | 2018 | 21 | 0.040 |
Why?
| | Intracranial Embolism and Thrombosis | 1 | 1998 | 6 | 0.040 |
Why?
| | Child | 3 | 2023 | 19129 | 0.040 |
Why?
| | New England | 1 | 1998 | 26 | 0.040 |
Why?
| | Coronary Thrombosis | 1 | 1998 | 25 | 0.040 |
Why?
| | Blood Sedimentation | 1 | 2017 | 34 | 0.040 |
Why?
| | Visual Acuity | 1 | 2020 | 272 | 0.040 |
Why?
| | Antibody Formation | 1 | 2019 | 276 | 0.040 |
Why?
| | Molecular Chaperones | 1 | 2019 | 174 | 0.040 |
Why?
| | Infusions, Intra-Arterial | 1 | 1997 | 46 | 0.040 |
Why?
| | Vulnerable Populations | 1 | 2019 | 147 | 0.040 |
Why?
| | Microtubule-Associated Proteins | 1 | 2019 | 188 | 0.040 |
Why?
| | Mitochondrial Proteins | 1 | 2019 | 226 | 0.040 |
Why?
| | Rheumatic Nodule | 1 | 2016 | 3 | 0.040 |
Why?
| | Osteoarthritis | 1 | 2019 | 176 | 0.040 |
Why?
| | RNA, Long Noncoding | 1 | 2019 | 161 | 0.040 |
Why?
| | Adsorption | 1 | 2016 | 129 | 0.040 |
Why?
| | Nutrition Surveys | 1 | 2017 | 233 | 0.040 |
Why?
| | Consensus | 1 | 2018 | 534 | 0.040 |
Why?
| | Drug Substitution | 1 | 2016 | 46 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2016 | 136 | 0.030 |
Why?
| | Thinness | 1 | 2016 | 91 | 0.030 |
Why?
| | Cerebrovascular Circulation | 1 | 1998 | 204 | 0.030 |
Why?
| | Protein Aggregates | 1 | 2016 | 70 | 0.030 |
Why?
| | Biopsy | 1 | 2020 | 1079 | 0.030 |
Why?
| | Observational Studies as Topic | 1 | 2016 | 89 | 0.030 |
Why?
| | Mortality | 1 | 2018 | 299 | 0.030 |
Why?
| | Lymphoma | 1 | 2016 | 180 | 0.030 |
Why?
| | Particle Size | 1 | 2016 | 345 | 0.030 |
Why?
| | Chemokines | 1 | 2016 | 230 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2019 | 539 | 0.030 |
Why?
| | Apolipoproteins E | 1 | 2015 | 90 | 0.030 |
Why?
| | Hypoglycemic Agents | 1 | 2022 | 1032 | 0.030 |
Why?
| | Leukemia | 1 | 2016 | 208 | 0.030 |
Why?
| | Interleukin-4 | 1 | 2015 | 215 | 0.030 |
Why?
| | Antigen-Antibody Complex | 1 | 2014 | 90 | 0.030 |
Why?
| | Cardiac Catheterization | 1 | 2018 | 541 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2014 | 175 | 0.030 |
Why?
| | Hospitals, Veterans | 1 | 2015 | 246 | 0.030 |
Why?
| | Causality | 1 | 2014 | 109 | 0.030 |
Why?
| | Life Style | 1 | 2016 | 430 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2019 | 1323 | 0.030 |
Why?
| | Body Weight | 1 | 2016 | 934 | 0.030 |
Why?
| | Blood Pressure | 1 | 2018 | 1664 | 0.020 |
Why?
| | Survival Rate | 1 | 2015 | 1720 | 0.020 |
Why?
| | Data Mining | 1 | 2011 | 113 | 0.020 |
Why?
| | HLA-DRB1 Chains | 1 | 2010 | 97 | 0.020 |
Why?
| | Propensity Score | 1 | 2011 | 242 | 0.020 |
Why?
| | Logistic Models | 1 | 2015 | 1901 | 0.020 |
Why?
| | Pancreatic Neoplasms | 1 | 2016 | 734 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2016 | 940 | 0.020 |
Why?
| | Smoking | 1 | 2016 | 1487 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 827 | 0.020 |
Why?
| | Risk | 1 | 2011 | 853 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 1997 | 2436 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 1012 | 0.020 |
Why?
| | American Heart Association | 1 | 1989 | 270 | 0.020 |
Why?
| | Congresses as Topic | 1 | 1989 | 204 | 0.020 |
Why?
| | Mice | 1 | 2024 | 15520 | 0.020 |
Why?
| | Lung | 1 | 2019 | 3664 | 0.020 |
Why?
| | Periodicals as Topic | 1 | 1989 | 191 | 0.020 |
Why?
| | Population Surveillance | 1 | 2009 | 413 | 0.020 |
Why?
| | Immunity, Innate | 1 | 2011 | 745 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2009 | 1129 | 0.020 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2220 | 0.010 |
Why?
| | Forecasting | 1 | 2004 | 353 | 0.010 |
Why?
| | Animals | 1 | 2024 | 33381 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 2004 | 965 | 0.010 |
Why?
|
|
Caplan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|